sis-PLA-tin
High Alert
Absorption: IV administration results in complete bioavailability.
Distribution: Widely distributed; accumulates for months.
Half-Life: 30–100 hr.
Contraindicated in:
Use Cautiously in:
Derm: alopecia
EENT: ototoxicity, tinnitus
F and E: hypocalcemia, hypokalemia, hypomagnesemia
GI: nausea, vomiting, diarrhea, HEPATOTOXICITY
GU: nephrotoxicity, sterility
Hemat: anemia, LEUKOPENIA, THROMBOCYTOPENIA
Local: phlebitis at IV site
Neuro: malaise, peripheral neuropathy, REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME (RPLS), SEIZURES, weakness
Misc: ANAPHYLAXIS
Drug-drug:
Lab Test Considerations:
IV Administration:
Cisplatin is a vesicant. If extravasation occurs, immediately stop infusion. Leave needle/cannula in place temporarily but do not flush the line. Gently aspirate extravasated solution; then remove needle/cannula. Elevate patient's extremity and apply dry cold compresses for 20 min 4 times day for 1–2 days. Initiate antidote (sodium thiosulfate). Inject 2 mL of a ⅙ molar sodium thiosulfate solution into existing IV line for each 100 mg of cisplatin extravasated; then consider also injecting a total of 1 mL as 0.1-mL SUBQ injections (total of 10 injections) around the area of extravasation in a clockwise manner; may repeat SUBQ injections several times over the next 3–4 hr. Topical dimethyl sulfoxide may also be considered. Apply dimethyl sulfoxide by saturating a gauze pad and painting on an area twice the size of the extravasation. Allow site to air-dry and repeat application every 8 hr for 7 days. Do not cover the area with dressing.
NDC Code